title: Second line treatment for EGFR wild-type advanced NSCLC: the jury is still out.
authors.affiliation: Frontier Science Foundation-Hellas & University of Athens, Athens, Greece.
authors.forename: U
authors.initials: U
authors.lastname: Dafni
authors.affiliation: Athens University of Economics and Business, Athens, Greece.
authors.forename: D
authors.initials: D
authors.lastname: Karlis
authors.affiliation: VU University Medical Center, Amsterdam, Netherlands.
authors.forename: E
authors.initials: E
authors.lastname: Smit
authors.affiliation: Oncology Department, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.. Electronic address: Solange.Peters@chuv.ch.
authors.forename: S
authors.initials: S
authors.lastname: Peters
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D017326:Clinical Trials, Phase III as Topic; D000077143:Docetaxel; D066246:ErbB Receptors / Q000235:genetics; D000069347:Erlotinib Hydrochloride; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D011799:Quinazolines / Q000627:therapeutic use*; D016879:Salvage Therapy / Q000379:methods; D043823:Taxoids / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D043823:Taxoids; D000077143:Docetaxel; D000069347:Erlotinib Hydrochloride; C512478:EGFR protein, human; D066246:ErbB Receptors
keywords: Adjusted HR; Advanced NSCLC; Docetaxel; Erlotinib; Phase III trial; Second line treatment; Tailor trial